AVTR: Avantor, Inc. Stock

by  •  • Comments Off on AVTR: Avantor, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 14,360.95
Enterprise Value ($M) 18,996.75
Book Value ($M) 5,553.20
Book Value / Share 8.16
Price / Book 2.59
NCAV ($M) -4,782.70
NCAV / Share -7.03
Price / NCAV -3.00

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.02
Return on Equity (ROE) 0.06

Liquidity (mrq)
Quick Ratio 1.06
Current Ratio 1.54

Balance Sheet (mrq) ($M)
Current Assets 2,504.70
Assets 12,840.60
Liabilities 7,287.40
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A T. Rowe Price Investment Management, Inc. 9.90 -3.69
08-09 13G/A Dodge & Cox 10.10 12.19
08-07 13G/A BlackRock, Inc. 10.80 59.97
02-16 13G/A Price T Rowe Associates Inc /md/ 2.90 0.00
02-13 13G/A Vanguard Group Inc 9.66 5.81

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-25 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-07-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-04-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-12-03 548,918 3,302,709 16.62
2024-12-02 475,747 3,858,515 12.33
2024-11-29 618,952 2,740,102 22.59

(click for more detail)

Similar Companies
A – Agilent Technologies, Inc. AME – AMETEK, Inc.
BIO – Bio-Rad Laboratories, Inc. BIO.B – Bio-Rad Laboratories, Inc.


Financial data and stock pages provided by
Fintel.io